Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: a Harmonising Outcome Measures for Eczema (HOME) statement
- 17 November 2016
- journal article
- review article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 176 (4), 979-984
- https://doi.org/10.1111/bjd.15179
Abstract
Background The Harmonising Outcome Measures for Eczema (HOME) initiative has defined four core outcome domains for a core outcome set (COS) to be measured in all atopic eczema (AE) trials to ensure cross‐trial comparison: clinical signs, symptoms, quality of life and long‐term control. Objectives The aim of this paper is to report on the consensus process that was used to select the core instrument to consistently assess symptoms in all future AE trials. Methods Following the HOME roadmap, two systematic reviews were performed which identified three instruments that had sufficient evidence of validity, reliability and feasibility to be considered for the final COS. Results At the fourth international HOME meeting, there was broad consensus among all stakeholders that the Patient‐Oriented Eczema Measure (POEM) should be used as the core instrument (87·5% agreed, 9·4% unsure, 3·1% disagreed). Conclusions All relevant stakeholders are encouraged to use POEM as the chosen instrument to measure the core domain of symptoms in all future AE clinical trials. Other instruments of interest can be used in addition to POEM.Keywords
Funding Information
- Swedish Asthma
- Allergy Association
- LEO Foundation
- Region of Skåne (county), Sweden
This publication has 21 references indexed in Scilit:
- The Harmonizing Outcome Measures for Eczema (HOME) Roadmap: A Methodological Framework to Develop Core Sets of Outcome Measurements in DermatologyJournal of Investigative Dermatology, 2015
- The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trialsJournal of Allergy and Clinical Immunology, 2014
- Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME)British Journal of Dermatology, 2014
- Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: A systematic reviewJournal of Allergy and Clinical Immunology, 2014
- Assessment of clinical signs of atopic dermatitis: A systematic review and recommendationJournal of Allergy and Clinical Immunology, 2013
- Developing core outcome sets for clinical trials: issues to considerTrials, 2012
- Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meetingAllergy, 2012
- Measurement in MedicinePublished by Cambridge University Press (CUP) ,2011
- Core Outcome Domains for Controlled Trials and Clinical Recordkeeping in Eczema: International Multiperspective Delphi Consensus ProcessJournal of Investigative Dermatology, 2011
- Harmonising Outcome Measures for Eczema (HOME).Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich, GermanyBritish Journal of Dermatology, 2010